Perceptive Imaging, a global leader in clinical trial imaging solutions for the clinical research community, announced the appointment of Doug Fulling as Chief Executive Officer, succeeding David Herron, who led the company since 2022. Fulling officially assumed his new role…
Calira, formerly known as Clustermarket, has announced a major rebrand and the appointment of Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), as a non-executive director and investor. The move underscores Calira’s strategy to strengthen its position…
HAP International announced today that, following a successful technical assessment of its TRACE ID program by U.S. Customs and Border Protection (CBP), both organizations are moving toward a formal Memorandum of Agreement (MOA). This milestone underscores CBP’s commitment to adopting…
Altoida, Inc., a trailblazer in AI- and augmented reality (AR)-based digital diagnostics for neurological conditions, has announced the appointment of three globally recognized experts to its Clinical and Scientific Advisory Board. The new members — Dr. Mona Flores, former Global…
Masimo (NASDAQ: MASI) announced compelling new findings from an exploratory analysis of its Investigation of Skin Pigmentation Effect on Performance of Pulse Oximetry (INSPIRE) feasibility study, published in CHEST Critical Care. Led by Dr. Andrew Goodwin and colleagues at the…
MaaT Pharma, a clinical-stage biotechnology company pioneering Microbiome Ecosystem Therapies™ (MET) to improve survival outcomes in patients with cancer through immune modulation, today announced the successful completion of the second pre-planned safety interim analysis of its ongoing Phase 2b PHOEBUS…
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule therapeutics for diseases with significant unmet needs, today announced the appointment of Bilal Arif as Chief Operating Officer (COO) and Linea Aspesi as Chief People Officer (CPO),…
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company pioneering precision medicines for neuropsychiatric disorders, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). This…
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca®) for the maintenance treatment of adults with extensive-stage small…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, announced two key executive appointments aimed at accelerating the development of its growing pipeline of novel antibody-drug conjugates (ADCs) and immunotherapies designed to treat difficult-to-manage solid tumors. The company has…